Quantcast
Last updated on April 16, 2014 at 1:21 EDT

Latest miconazole Stories

2013-03-12 04:21:10

TOKYO, March 12, 2013 /PRNewswire/ -- Sosei Group Corporation (TSE Mothers Index: 4565), the biopharmaceutical company, today announces that its Japanese subsidiary, Sosei Co., Ltd., has initiated a Phase III trial for SO-1105 for the treatment of oropharyngeal candidiasis. The study is an open-label, randomised, multiple centres, parallel-group design (with open active comparator miconazole gel), and will assess efficacy and safety of SO-1105. SO-1105 is an...

2012-05-30 22:21:54

EL SEGUNDO, Calif., May 31, 2012 /PRNewswire/ -- Conazol, a leading over-the-counter Athlete's Foot treatment in Mexico for over 10 years, is now available in the U.S. The trusted and effective brand is expanding its U.S. distribution and can be found at retailers including Walmart and Target in key U.S. Hispanic markets, such as Los Angeles, Houston, Dallas and Chicago. The brand is being supported by a multi-market promotional campaign that includes Spanish language TV advertising....

2010-04-16 12:17:00

WOODCLIFF LAKE, N.J., April 16 /PRNewswire/ -- Strativa Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved Oravig (miconazole) buccal tablets for the treatment of oropharyngeal candidiasis (OPC), more commonly known as thrush, in adults and children age 16 and older. Oravig is the first and only local, oral prescription formulation of miconazole - an antifungal medication - approved for this use in the U.S. Oravig, which adheres to the gum,...

2009-09-14 13:29:00

WOODCLIFF LAKE, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that its development partner BioAlliance Pharma SA presented Phase III study results for miconazole Lauriad(R) mucoadhesive buccal tablets (MBT) that demonstrate noninferiority to clotrimazole troches for oropharyngeal candidiasis (OPC), an opportunistic infection of the mouth and throat. The data from this...

2009-08-19 07:00:00

WOODCLIFF LAKE, N.J., Aug. 19 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced that the U.S. Food and Drug Administration (FDA) has accepted the new drug application (NDA) for miconazole Lauriad((R)) mucoadhesive buccal tablets (MBT) to treat oropharyngeal candidiasis (OPC). Miconazole MBT delivers the antifungal miconazole via a mucoadhesive buccal tablet...